4.8 Article

Synergistic Cancer Photochemotherapy via Layered Double Hydroxide-Based Trimodal Nanomedicine at Very Low Therapeutic Doses

Journal

ACS APPLIED MATERIALS & INTERFACES
Volume 13, Issue 6, Pages 7115-7126

Publisher

AMER CHEMICAL SOC
DOI: 10.1021/acsami.0c23143

Keywords

layered double hydroxide; multifunctional nanomedicine; simultaneous photothermal/photodynamic therapy triggered by the same NIR laser; pH-sensitive prodrug cancer chemotherapy; synergistic cancer photochemotherapy

Funding

  1. Australian Research Council (ARC) Discovery Project [DP170104643, DP190103486]
  2. DECRA Fellowship [DE170100092]
  3. National Health and Medical Research Council [APP1175808]

Ask authors/readers for more resources

A novel trifunctional LDH nanosystem was developed for combined photochemotherapy of skin cancer by releasing drugs in an acid-triggered manner and generating heating and reactive oxygen species upon laser irradiation, which nearly eradicated tumor tissues with minimal side effects.
The success of cancer therapy is always accompanied by severe side effects due to the high amount of toxic antitumor drugs that off-target normal organs/tissues. Herein, we report the development of a trifunctional layered double hydroxide (LDH) nanosystem for combined photochemotherapy of skin cancer at very low therapeutic doses. This nanosystem (ICG/Cu-LDH@BSA-DOX) is composed of acid-responsive bovine serum albumin-doxorubicin prodrug (BSA-DOX) and indocyanine green (ICG)-intercalated Cu-doped LDH nanoparticle. ICG/Cu-LDH@BSA-DOX is able to release DOX in an acid-triggered manner, efficiently and simultaneously generates heating and reactive oxygen species (ROS) upon 808 nm laser irradiation, and synergistically induces apoptosis of skin cancer cells. In vivo therapeutic evaluations demonstrate that ICG/Cu-LDH@BSA-DOX nearly eradicated the tumor tissues upon one-course treatment using very low doses of therapeutic agents (0.175 mg/kg DOX, 0.5 mg/kg Cu, and 0.25 mg/kg ICG) upon very mild 808 nm laser irradiation (0.3 W/cm(2) for 2 min). This work thus provides a novel strategy to design anticancer nanomedicine for efficient combination cancer treatment with minimal side effects in clinical applications.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available